|
Adenovirus Epidemic Keratoconjunctivitis (EKC) is a
highly contagious epidemic disease. Symptoms of EKC include
conjunctival redness, swelling or redness of the eyelid,
discharge from the eye, sticking of eyelids, pain or
discomfort in the eye and photophobia. In 20-50% of cases,
corneal opacities can persist for weeks to months to several
years. There is no specific antiviral chemotherapy against
Adenoviruses at present. Corticosteroids may be used to
limit corneal damage but can have significant side effects
and also interfere with viral clearance.
The efficacy
of CTC-96 on Human Adenovirus type 5 (Ad5) has been shown in
both tissue culture and rabbit eyes. The combined anti-viral
and anti-inflammatory actions of Doxovir™ may make it a
choice drug for ocular adenoviruses.
The FDA has approved Doxovir™ as an Investigational New Drug for Adenovirus-derived Keratoconjunctivitis application. Redox Pharmaceutical Corporation has successfully concluded Phase I clinical trials for this application. Phase II clinical trials for Adenovirus-derived Keratoconjunctivitis application are being performed under licensing to OPKO Health Inc. who have acquired exclusive worldwide rights to our novel new drug for the Adenovirus-derived Keratoconjunctivitis application.
|
